At a glance
ClinicalIndex Comparison RecordPhase 2Active· 306 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib for Chronic Lymphocytic Leukemia and 3 related conditions. Active but no longer recruiting, targeting 306 participants across 12 sites in 3 countries.
Detailed Summary
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
CountriesItaly, United Kingdom, United States
Collaborators--
Timeline
Phase 2Active
20142015201620172018201920202021202220232024202520262027
First PostedJan 2014
Enrollment StartJan 2014
Primary CompletionJul 2021
TodayJul 2026
Study CompletionJun 2027
First PostedJan 8, 2014
Enrollment StartJan 30, 2014
Primary CompletionJul 15, 2021
Study CompletionJun 9, 2027
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 12.5 years ago
Interventions
Acalabrutinibdrug
Participants will receive acalabrutinib as stated in the arms' description.